A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Trial Profile

A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Liposarcoma
  • Focus Therapeutic Use
  • Sponsors Vector Oncology Solutions LLC
  • Most Recent Events

    • 18 Aug 2017 Results published in the Cancer.
    • 18 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top